RecruitingPhase 1NCT07613710

A Trial to Test the Safety and Tolerability of Lu AH69593 in Adults That Are Healthy or Have Narcolepsy

Interventional, Randomized, Double-blind, Sequential-group, Placebo-controlled, Single- and Multiple-ascending-dose Trial Investigating Safety, Tolerability, and Pharmacokinetics of Lu AH69593 in Healthy Participants, Including Open-label Cohorts to Explore Pharmacodynamic Properties in Participants With Narcolepsy, and Food Effect in Healthy Participants


Sponsor

H. Lundbeck A/S

Enrollment

104 participants

Start Date

Jun 13, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

The purpose of the trial is to determine if Lu AH69593 is safe and well tolerated. The trial will also look at how the body processes Lu AH69593 with and without food.


Eligibility

Min Age: 18 YearsMax Age: 64 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Lu AH69593 and a drug called Placebo for people with narcolepsy. The study is currently recruiting participants at 2 locations. People eligible for this study include aged 18 Years to 64 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGLu AH69593

Lu AH69593 will be administered per schedule specified in the arm description.

DRUGPlacebo

Placebo will be administered per schedule specified in the arm description.


Locations(2)

Terveystalo Helsinki, Sleep Clinic

Helsinki, Finland

CRST, Clinical Research Services Turku

Turku, Finland

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07613710


Related Trials